Alzheimer, cardiovascular disease, chemotherapy-resistant cancers- all these conditions remain incurable. We will develop tiny particles, nanocarriers, for treatment of such conditions. Our unique approach is to encapsulate Proteolysis Targeting Chimeras (PROTACs) in nanocarriers. PROTACs are novel, revolutionary drugs that degrade “bad” proteins involved in these conditions. PROTACs were efficient in initial experiments. However, major challenges hamper PROTACs performance: stabilization of PROTACs in blood, and targeting the diseased cells. Encapsulation of PROTACs in nanocarriers will tackle these challenges, leading to new treatments of major public health problems in the future.